Capricor's Deramiocel BLA at Risk as FDA Publicly Rejects HOPE-3 Trial's Positive Claims

FDA Disputes Capricor's Phase 3 DMD Cell Therapy Claims

The FDA has publicly disagreed with Capricor Therapeutics' assertion that its Phase 3 HOPE-3 trial for deramiocel in Duchenne muscular dystrophy met its primary and secondary endpoints. In briefing documents released ahead of an advisory committee meeting, the agency stated the study showed no statistically significant difference between deramiocel and placebo at 12 months. The FDA cited changes made to the pre-specified statistical analysis plan (SAP) during the open-label extension period, including modifications to endpoint definitions, analytical methods, and data imputation. Concerns about the effectiveness of blinding due to a distinctive adverse event profile were also raised. Capricor's CEO, Linda Marbán, strongly refutes the FDA's analysis, claiming the agency used an outdated and incomplete SAP version 1.1 instead of the final SAP version 3.0, which governed their reported positive results.

• The FDA's briefing documents specifically detail that the HOPE-3 trial did not achieve its pre-specified primary and secondary efficacy endpoints, showing no statistically significant difference between deramiocel and placebo at 12 months. The agency's concerns primarily revolve around post-hoc modifications to the statistical analysis plan (SAP), including changes to endpoint definitions, analytical methods, and data imputation strategies, which occurred during the open-label extension phase.
• Capricor Therapeutics vehemently challenges the FDA's methodology, asserting that the agency's analysis relies on an obsolete and incomplete internal draft (SAP version 1.1) rather than the company's final, pre-unblinding SAP version 3.0. Capricor maintains that under their governing SAP, the trial demonstrated a statistically significant benefit on the primary endpoint of upper limb performance, supported by improvements in cardiac function, and that the treatment effect has been consistent across trials.
• A critical point of contention raised by the FDA is the potential compromise of trial blinding. Reviewers noted a significant difference in adverse event profiles, with 42% of deramiocel-treated patients experiencing hypersensitivity reactions compared to 15% in the placebo group. This disparity, according to the FDA, raises the possibility that treatment assignment could have been inferred, even under formal blinding conditions, thereby impacting the trial's integrity.

FDA Disputes Deramiocel's HOPE-3 Efficacy Claims for DMD

Recent clinical investigations in Duchenne muscular dystrophy (DMD) have yielded mixed results, particularly in the gene therapy space. The Phase 3 CIFFREO trial evaluated fordadistrogene movaparvovec, an investigational AAV9-based mini-dystrophin gene therapy, in ambulatory boys aged 4 to 8 years. The double-blind, placebo-controlled study did not meet its primary efficacy endpoint, which was the change from baseline in the North Star Ambulatory Assessment (NSAA) total score at 52 weeks. The least squares mean change was 1.46 for the treatment group versus 1.37 for placebo, a statistically insignificant difference (p=0.91). Furthermore, the therapy was associated with a higher rate of adverse events (99% vs. 77% in placebo) and serious adverse events (32% vs. 14%), leading to a negative benefit-risk assessment and the discontinuation of the agent's clinical development by the sponsor.

In contrast, trials investigating alternative steroidal therapies have shown more promise. The VBP15-002 and VBP15-004 trials assessed vamorolone in steroid-naïve boys with DMD aged 4 to <7 years. The studies found that all five motor outcomes measured, including the NSAA and 6-Minute Walk Distance (6MWD), were sensitive to the drug's effect, demonstrating efficacy. Crucially, vamorolone was found to have an improved safety profile compared to standard corticosteroids. Conversely, the Phase 3 TAMDMD trial, which investigated tamoxifen as an adjunct to corticosteroids, did not demonstrate a sustained or timing effect on motor function. While well-tolerated, the trial failed to provide evidence that prolonged tamoxifen treatment is effective in delaying disease progression.

Beyond pharmacological interventions, research has also explored novel device-based and preclinical evaluation platforms. A study of a lightweight (440 g) soft shoulder exosuit in eight individuals with DMD reported no adverse events and demonstrated significant functional benefits. The device improved active range of motion in shoulder abduction by 57.45% and increased upper limb functional performance scores. In the preclinical realm, a study using patient-derived MYOrganoids evaluated AAV-mediated microdystrophin (µDys) gene therapy. While the therapy improved muscle resistance and partially restored membrane stability, it failed to reduce profibrotic signaling. This finding highlights the persistence of fibrotic activity post-gene therapy, an important consideration for the development and refinement of future genetic treatments.

The Persistent Unmet Need in Duchenne Muscular Dystrophy

Despite a wave of recently approved therapies, Duchenne muscular dystrophy (DMD) remains a disease with substantial unmet need. Efficacy data for many novel agents are still maturing, cardiac involvement continues to be inadequately addressed, and structural inequities in healthcare delivery and provider knowledge further compound the gap between therapeutic innovation and real-world patient outcomes.

• Limited long-term efficacy evidence: While FDA-approved RNA-based and microdystrophin gene therapies (e.g., delandistrogene moxeparvovec) show mechanistic promise, clinical evidence remains limited, with high heterogeneity across trials and a continued need for long-term randomized controlled trials to confirm durable safety and efficacy; current treatments still fail to meaningfully alter the poor long-term prognosis for many patients.

• Persistent cardiac targeting gap: Cardiac involvement remains inadequately addressed by existing therapies, with substantial challenges in achieving effective, cardiac-specific delivery given the complex interplay between cardiac and skeletal muscle pathophysiology.

• Immaturity of cell-based approaches: Advanced cell-based strategies—including 2D cell sheets, patches, and engineered 3D cardiac models derived from human-induced pluripotent stem cells—remain largely speculative for direct therapeutic use in DMD, hampered by extensive muscle mass loss, unresolved issues in cell integration and maturation, and uncertain long-term functional outcomes; as such, genetic approaches currently take precedence over cell-based therapies.

• Ongoing safety and scalability concerns: Ensuring long-term safety and developing therapies that can be scaled across the broader DMD population remain significant, unresolved challenges for the field.

• Healthcare access disparities: Data from Brazil illustrate stark inequities—public-sector patients faced diagnostic delays averaging 25 months (versus 10 months in private care), lacked funded genetic testing, experienced delayed corticosteroid initiation, and had limited access to multidisciplinary care and medical devices. These gaps translated into earlier loss of ambulation (11–12 years vs. 13–14 years) and markedly reduced life expectancy (19–20 years vs. 26–27 years) compared to privately insured patients.

• Provider knowledge and infrastructure gaps: Survey data from China revealed an overall DMD awareness rate of only 54.64% among medical staff, with particularly low awareness of diagnostic genomics (67.74%) and orphan drug policy (42.74%), and systematically lower awareness among nursing staff—underscoring the need for targeted, competency-based training rather than generic professional education.

• Regulatory and infrastructure prerequisites: As with many rare diseases, therapies often enter clinical trials before standardized care protocols, validated outcome measures correlating with clinical benefit, and comprehensive natural history data are fully established—each a prerequisite for robust regulatory evaluation and approval.

• Historical treatment stagnation: Until relatively recently, disease-modifying intervention was largely limited to glucocorticoid steroids, reflecting decades of minimal therapeutic progress and underscoring why current advances, though promising, are still measured against a backdrop of longstanding therapeutic inertia.